The Company’s board of directors intends to appoint J. Scott Wolchko, the Company’s President and Chief Executive Officer, to succeed Mr. Dulac as the Company’s Chief Financial Officer and also serve as the Company’s principal financial and accounting officer, effective immediately after Mr. Dulac’s resignation.
On May 30, 2024, Edward J. Dulac III provided notice of his resignation from his position as Chief Financial Officer of Fate Therapeutics, Inc. (the “Company”), which will be effective June 14, 2024.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 1.0
J. Scott Wolchko was appointed as Chief Financial Officer at FATE THERAPEUTICS INC.
Action
appointed
Role
Chief Financial Officer
Exact text from the filing
The Company’s board of directors intends to appoint J. Scott Wolchko, the Company’s President and Chief Executive Officer, to succeed Mr. Dulac as the Company’s Chief Financial Officer and also serve as the Company’s principal financial and accounting officer, effective immediately after Mr. Dulac’s resignation.
Edward J. Dulac III resigned as Chief Financial Officer at FATE THERAPEUTICS INC.
Action
resigned
Role
Chief Financial Officer
Exact text from the filing
On May 30, 2024, Edward J. Dulac III provided notice of his resignation from his position as Chief Financial Officer of Fate Therapeutics, Inc. (the “Company”), which will be effective June 14, 2024.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.